| Summary of Net Revenue, Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales,
operating profit, depreciation and amortization, interest expense,
income tax (expense) benefit, other comprehensive loss, and assets
for the years ended November 30, 2017 and 2016:
|
|
|
|
|
|
|
|
|
| |
|
For the years ended November 30, |
|
| |
|
2017 |
|
|
2016 |
|
|
Net revenue:
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
24,942,089 |
|
|
$ |
22,777,919 |
|
|
PrepaCyte CB
|
|
|
442,190 |
|
|
|
350,128 |
|
|
|
|
|
|
|
|
|
|
|
Total net revenue
|
|
$ |
25,384,279 |
|
|
$ |
23,128,047 |
|
|
|
|
|
|
|
|
|
|
|
Cost of sales:
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
6,257,628 |
|
|
$ |
5,446,126 |
|
|
PrepaCyte CB
|
|
|
466,763 |
|
|
|
328,674 |
|
|
|
|
|
|
|
|
|
|
|
Total cost of sales
|
|
$ |
6,724,391 |
|
|
$ |
5,774,800 |
|
|
|
|
|
|
|
|
|
|
|
Operating profit:
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
5,067,228 |
|
|
$ |
2,447,160 |
|
|
PrepaCyte CB
|
|
|
(61,002 |
) |
|
|
(2,013,566 |
) |
|
|
|
|
|
|
|
|
|
|
Total operating profit
|
|
$ |
5,006,226 |
|
|
$ |
433,594 |
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization:
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
193,741 |
|
|
$ |
240,916 |
|
|
PrepaCyte CB
|
|
|
36,254 |
|
|
|
45,734 |
|
|
|
|
|
|
|
|
|
|
|
Total depreciation and amortization
|
|
$ |
229,995 |
|
|
$ |
286,650 |
|
|
|
|
|
|
|
|
|
|
|
Interest expense:
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
1,302,650 |
|
|
$ |
925,075 |
|
|
PrepaCyte CB
|
|
|
— |
|
|
|
22,265 |
|
|
|
|
|
|
|
|
|
|
|
Total interest expense
|
|
$ |
1,302,650 |
|
|
$ |
947,340 |
|
|
|
|
|
|
|
|
|
|
|
Income tax (expense) benefit:
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
(1,308,603 |
) |
|
$ |
1,141,823 |
|
|
PrepaCyte CB
|
|
|
— |
|
|
|
17,589 |
|
|
|
|
|
|
|
|
|
|
|
Total income tax (expense) benefit
|
|
$ |
(1,308,603 |
) |
|
$ |
1,159,412 |
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
6,457 |
|
|
$ |
(135,524 |
) |
|
PrepaCyte CB
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total other comprehensive income (loss)
|
|
$ |
6,457 |
|
|
$ |
(135,524 |
) |
|
|
|
|
|
|
|
|
|
The following table shows the assets by segment as of
November 30 2017 and November 30, 2016:
|
|
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
23,360,714 |
|
|
$ |
18,960,261 |
|
|
PrepaCyte CB
|
|
|
549,283 |
|
|
|
578,207 |
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$ |
23,909,997 |
|
|
$ |
19,538,468 |
|
|
|
|
|
|
|
|
|
|
|